Celldex Therapeutics (CLDX) Change in Acquisitions & Divestments (2010 - 2026)

Celldex Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 31.62% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $534.6 million (down 13.69% YoY), while the FY2025 annual figure was $596.3 million, up 18.85% from the prior year.
• Change in Acquisitions & Divestments was $133.4 million for Q1 2026 at Celldex Therapeutics, up from $111.5 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $195.0 million in Q1 2025 to a low of $27.8 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $107.8 million across 5 years, with a median of $111.5 million in 2025.
• Biggest YoY gain for Change in Acquisitions & Divestments was 562.38% in 2022; the steepest drop was 64.3% in 2022.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $87.8 million in 2022, then fell by 19.26% to $70.9 million in 2023, then soared by 117.2% to $154.0 million in 2024, then retreated by 27.59% to $111.5 million in 2025, then climbed by 19.61% to $133.4 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $133.4 million (Q1 2026), $111.5 million (Q4 2025), and $116.9 million (Q3 2025), per Business Quant data.